Skip to main content
Premium Trial:

Request an Annual Quote

Origene Collaborating with PROOF Centre on Protein Diagnostics for Heart and Kidney Transplants

Premium

Canada's Centre of Excellence for the Prevention of Organ Failure – also called the PROOF Centre – has partnered with Origene Technologies on blood-based protein assays for monitoring heart and kidney transplantation.

The agreement covers a multi-year project that aims to provide monitoring and predictive blood tests for heart and kidney transplant patients. Origene will use its experience in monoclonal antibody production and Luminex multiplex assay development to build and implement diagnostic assays for transplant care, the company said in a statement.

It added that this was "the first announced clinical development project" using Origene's UltraMAB antibodies – a recently released line of antibodies that the company said are "validated for specificity and low cross-reactivity."

According to a recent study by the PROOF Centre, implementation of blood-based protein tests for organ rejection could save British Columbia up to C$700,000 (US$700,000) over five years.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more